Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05759923 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05759923 · ClinicalTrials.gov record · last posted 2026-07-31

First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours

StatusRecruiting
PhasePhase 1
Started2023-01-26
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The goal of this clinical trial is to learn if the OATD-02 administration (orally) in monotherapy is safe and has the pharmacodynamic potential to restore and enhance tumour responses to immunotherapy through increased arginine levels or intrinsic anti-tumour activity in participants with advanced metastatic colorectal cancer, ovarian cancer, renal cancer or pancreatic cancer.

Protocol amendment history 2 changes detected by DataLookout

2026-08-01
Primary completion pushed: 2025-12 → 2027-03-31
2026-08-01
Completion pushed: 2025-12 → 2027-03-31
Trial Details
NCT Number NCT05759923
Lead Sponsor Molecure S.A.
Conditions Advanced Ovarian Carcinoma, Advanced Renal Cell Carcinoma, Advanced Pancreatic Carcinoma, Advanced Colorectal Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Ovarian Carcinoma
Enrollment 40 participants
Start Date 2023-01-26
Primary Completion 2027-03-31 (estimated)
Study Completion 2027-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-31